The neurobiological basis of attention-deficit/hyperactivity disorder

Primary Psychiatry

Volumn 16, Issue 7, 2009, Pages 47-54

  Arnsten, Amy F T ^a   Berridge, Craig W ^b   McCracken, James T ^c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; ATOMOXETINE; CATECHOLAMINE; GUANFACINE; NORADRENALIN;

ATTENTION DEFICIT DISORDER; BEHAVIOR CONTROL; DISEASE ASSOCIATION; HUMAN; MENTAL DISEASE; NEUROBIOLOGY; PREFRONTAL CORTEX; REVIEW;

EID: 75449101588     PISSN: 10826319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (103)

1. Robbins TW. Shifting and stopping: fronto-striatal substrates, neurochemical modulation and clinical implications. Philos Trans R Soc Lond B Biol Sci. 2007;362(1481):917-932.
2. Rubia K, Overmeyer S, Taylor E, et al. Hypofrontality in attention deficit hyperactivity disorder during higher-order motor control: a study with functional MRI. Am J Psychiatry. 1999;156(6):891-896.
3. Faraone SV, Perlis RH, Doyle AE, et al. Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005;57(11):1313-1323.
4. Volkow ND, Wang GJ, Newcorn J, et al. Depressed dopamine activity in caudate and preliminary evidence of limbic involvement in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 2007;64(8):932-940.
5. Berridge CW, Devilbiss DM, Andrzejewski ME, et al. Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. Biol Psychiatry. 2006;60(10):1111-1120.
6. Nigg JT. Neuropsychologic theory and findings in attention-deficit/ hyperactivity disorder: the state of the field and salient challenges for the coming decade. Biol Psychiatry. 2005;57(11):1424-1435.
7. Posner MI, Petersen SE. The attention system of the human brain. Annu Rev Neurosci. 1990;13:25-42.
8. Knudsen EI. Fundamental components of attention. Annu Rev Neurosci. 2007;30:57-78.
9. Mesulam MM. From sensation to cognition [review]. Brain. 1998;121(Pt 6):1013-1052.
10. Desimone R. Visual attention mediated by biased competition in extrastriate visual cortex. Philos Trans R Soc Lond B Biol Sci. 1998;353(1373):1245-1255.
11. Buschman TJ, Miller EK. Top-down versus bottom-up control of attention in the prefrontal and posterior parietal cortices. Science. 2007;315(5820):1860-1862.
12. Fujita I, Tanaka K, Ito M, Cheng K. Columns for visual features of objects in monkey inferotemporal cortex. Nature. 1992;360(6402):343-346.
13. Desimone R. Neural mechanisms for visual memory and their role in attention. Proc Natl Acad Sci USA. 1996;93(24):13494-13499.
14. Coull JT, Nobre AC. Where and when to pay attention: the neural systems for directing attention to spatial locations and to time intervals as revealed by both PET and fMRI. J Neurosci. 1998;18(18):7426-7435.
15. Rudolph K, Pasternak T. Transient and permanent deficits in motion perception after lesions of cortical areas MT and MST in the macaque monkey. Cereb Cortex. 1999;9(1):90-100.
16. Snyder LH, Grieve KL, Brotchie P, Andersen RA. Separate body- and world-referenced representations of visual space in parietal cortex. Nature. 1998;394(6696):887-891.
17. Crowe DA, Chafee MV, Averbeck BB, Georgopoulos AP. Neural activity in primate parietal area 7a related to spatial analysis of visual mazes. Cereb Cortex. 2004;14(1):23-34.
18. Ungerleider LA. The corticocortical pathways for object recognition and spatial perception. In: Chagas C, Gattass R, Gross C, eds. Pattern Recognition Mechanisms. Rome, Italy: The Pontifical Academy of Sciences; 1985:21-37.
19. Friedman-Hill SR, Robertson LC, Treisman A. Parietal contributions to visual feature binding: evidence from a patient with bilateral lesions. Science. 1995;269(5225):853-855.
20. Gazzaley A, Rissman J, Cooney J, et al. Functional interactions between prefrontal and visual association cortex contribute to top-down modulation of visual processing. Cereb Cortex. 2007;17(suppl 1):i125-i135.
21. Chao LL, Knight RT. Human prefrontal lesions increase distractibility to irrelevant sensory inputs. Neuroreport. 1995;6(12):1605-1610.
22. Moore T, Armstrong KM. Selective gating of visual signals by microstimulation of frontal cortex. Nature. 2003;421(6921):370-373.
23. Wilkins AJ, Shallice T, McCarthy R. Frontal lesions and sustained attention. Neuropsychologia. 1987;25(2):359-365.
24. Bunge SA, Ochsner KN, Desmond JE, Glover GH, Gabrieli JD. Prefrontal regions involved in keeping information in and out of mind. Brain. 2001;124(Pt 10):2074-2086.
25. Arnsten AF, Steere JC, Hunt RD. The contribution of á2- noradrenergic mechanisms to prefrontal cortical cognitive function. Potential significance for attention-deficit hyperactivity disorder. Arch Gen Psychiatry. 1996;53(5):448-455.
26. French GM. Locomotor effects of regional ablations of frontal cortex in rhesus monkeys. J Comp Physiol Psychol. 1959;52(1):18-24.
27. Drewe EA. Go - no go learning after frontal lobe lesions in humans. Cortex. 1975;11(1):8-16.
28. Middleton FA, Strick PL. Basal ganglia and cerebellar loops: motor and cognitive circuits. Brain Res Brain Res Rev. 2000;31(2-3):236-250.
29. Clark L, Blackwell AD, Aron AR, et al. Association between response inhibition and working memory in adult ADHD: a link to right frontal cortex pathology? Biol Psychiatry. 2007;61(12):1395-1401.
30. Aron AR, Robbins TW, Poldrack RA. Inhibition and the right inferior frontal cortex. Trends Cog Sci. 2004;8(4):170-177.
31. Chambers CD, Bellgrove MA, Stokes MG, et al. Executive "brake failure" following deactivation of human frontal lobe. J Cogn Neurosci. 2006;18(3):444-455.
32. Kuczenski R, Segal DS. Exposure of adolescent rats to oral methylphenidate: preferential effects on extracellular norepinephrine and absence of sensitization and cross-sensitization to methamphetamine. J Neurosci. 2002;22(16):7264-7271.
33. Lewis DA. The catecholamine innervation of primate cerebral cortex. In: Solanto MV, Arnsten AF, Castellanos FX, eds. Stimulant Drugs and ADHD: Basic and Clinical Neuroscience. New York, NY: Oxford University Press; 2001:77-103.
34. MacDonald E, Kobilka BK, Scheinin M. Gene targeting-homing in on alpha 2-adrenoceptor-subtype function. Trends Pharmacol Sci. 1997;18(6):211-219.
35. Arnsten AF. Catecholamine and second messenger influences on prefrontal cortical networks of "representational knowledge": a rational bridge between genetics and the symptoms of mental illness. Cereb Cortex. 2007;17(suppl 1):i6-i15.
36. Brozoski TJ, Brown RM, Rosvold HE, Goldman PS. Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey. Science. 1979;205(4409):929-932.
37. Wang M, Ramos BP, Paspalas CD, et al. α2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortex. Cell. 2007;129(2):397-410.
38. Cedarbaum JM, Aghajanian GK. Catecholamine receptors on locus coeruleus neurons: pharmacological characterization. Eur J Pharmacol. 1977;44(4):375-385.
39. U'Prichard DC, Bechtel WD, Rouot BM, Snyder SH. Multiple apparent alpha-noradrenergic receptor binding sites in rat brain: effect of 6-hydroxydopamine. Mol Pharmacol. 1979;16(1):47-60.
40. Smiley JF, Williams SM, Szigeti K, Goldman-Rakic PS. Light and electron microscopic characterization of dopamine-immunoreactive axons in human cerebral cortex. J Comp Neurol. 1992;321(3):325-335.
41. Sawaguchi T, Goldman-Rakic PS. D1 dopamine receptors in prefrontal cortex: involvement in working memory. Science. 1991;251(4996):947-950.
42. Li BM, Mei ZT. Delayed-response deficit induced by local injection of the α2-adrenergic antagonist yohimbine into the dorsolateral prefrontal cortex in young adult monkeys. Behav Neural Biol. 1994;62(2):134-139.
43. Chamberlain SR, Muller U, Blackwell AD, Clark L, Robbins TW, Sahakian BJ. Neurochemical modulation of response inhibition and probabilistic learning in humans. Science. 2006;311(5762):861-863.
44. Ma CL, Arnsten AF, Li BM. Locomotor hyperactivity induced by blockade of prefrontal cortical α2-adrenoceptors in monkeys. Biol Psychiatry. 2005;57(2):192-195.
45. Ma CL, Qi XL, Peng JY, Li BM. Selective deficit in no-go performance induced by blockade of prefrontal cortical 2-adrenoceptors in monkeys. Neuroreport. 2003;14(7):1013-1016.
46. Avery RA, Franowicz JS, Studholme C, van Dyck CH, Arnsten AF. The alpha-2A-adrenoceptor agonist, guanfacine, increases regional cerebral blood flow in dorsolateral prefrontal cortex of monkeys performing a spatial working memory task. Neuropsychopharmacology. 2000;23(3):240-249.
47. O'Neill J, Fitten LJ, Siembieda DW, Ortiz F, Halgren E. Effects of guanfacine on three forms of distraction in the aging macaque. Life Sci. 2000;67(8):877-885.
48. Arnsten AF. The biology of being frazzled. Science. 1998;280(5370):1711-1712.
49. Birnbaum S, Gobeske KT, Auerbach J, Taylor JR, Arnsten AF. A role for norepinephrine in stress-induced cognitive deficits: á.1-adrenoceptor mediation in the prefrontal cortex. Biol Psychiatry. 1999;46(9):1266- 1274.
50. Ramos BP, Colgan L, Nou E, Ovadia S, Wilson SR, Arnsten AF. The beta-1 adrenergic antagonist, betaxolol, improves working memory performance in rats and monkeys. Biol Psychiatry. 2005;58(11):894-900.
51. Vijayraghavan S, Wang M, Birnbaum SG, Williams GV, Arnsten AF. Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory. Nat Neurosci. 2007;10(3):376-384.
52. Birnbaum SG, Yuan PX, Wang M, et al. Protein kinase C overactivity impairs prefrontal cortical regulation of working memory. Science. 2004;306(5697):882-884.
53. Loo SK, Humphrey LA, Tapio T, et al. Executive functioning among Finnish adolescents with attentiondeficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(12):1594-1604.
54. Bush G, Valera EM, Seidman LJ. Functional neuroimaging of attention-deficit/hyperactivity disorder: a review and suggested future directions. Biol Psychiatry. 2005;57(11):1273-1284.
55. Sheridan MA, Hinshaw S, D'Esposito M. Efficiency of the prefrontal cortex during working memory in attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(10):1357-1366.
56. Castellanos FX, Lee PP, Sharp W, et al. Developmental trajectories of brain volume abnormalities in children and adolescents with attention-deficit/ hyperactivity disorder. JAMA. 2002;288(14):1740-1748.
57. Casey BJ, Epstein JN, Buhle J, et al. Frontostriatal connectivity and its role in cognitive control in parentchild dyads with ADHD. Am J Psychiatry. 2007;164(11):1729-1736.
58. Makris N, Buka SL, Biederman J, et al. Attention and executive systems abnormalities in adults with childhood ADHD: A DT-MRI Study of connections. Cereb Cortex. 2008;18(5):11210-11220.
59. Shaw P, Eckstrand K, Sharp W, et al. Attention-deficit/hyperactivity disorder is characterized by a delay in cortical maturation. Proc Natl Acad Sci U S A. 2007;104(49):19649-19654.
60. Makris N, Biederman J, Valera EM, et al. Cortical thinning of the attention and executive function networks in adults with attention-deficit/ hyperactivity disorder. Cereb Cortex. 2007;17(6):1364-1375.
61. Seidman LJ, Valera EM, Makris N, et al. Dorsolateral prefrontal and anterior cingulate cortex volumetric abnormalities in adults with attention-deficit/hyperactivity disorder identified by magnetic resonance imaging. Biol Psychiatry. 2006;60(10):1071-1080.
62. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: Americn Psychiatric Association; 2000.
63. Witte EA, Marrocco RT. Alteration of brain noradrenergic activity in rhesus monkeys affects the alerting component of covert orienting. Psychopharmacology (Berl). 1997;132(4):315-323.
64. Bobb AJ, Addington AM, Sidransky E, et al. Support for association between ADHD and two candidate genes: NET1 and DRD1. Am J Med Genet B Neuropsychiatr Genet. 2005;134(1):67-72.
65. Daly G, Hawi Z, Fitzgerald M, Gill M. Mapping susceptibility loci in attention deficit hyperactivity disorder: preferential transmission of parental alleles at DAT1, DBH and DRD5 to affected children. Mol Psychiatry. 1999;4(2):192-196.
66. Tahir E, Yazgan Y, Cirakoglu B, Ozbay F, Waldman I, Asherson PJ. Association and linkage of DRD4 and DRD5 with attention deficit hyperactivity disorder (ADHD) in a sample of Turkish children. Mol Psychiatry. 2000;5(4):396-404.
67. Kustanovich V, Ishii J, Crawford L, et al. Transmission disequilibrium testing of dopamine-related candidate gene polymorphisms in ADHD: confirmation of association of ADHD with DRD4 and DRD5. Mol Psychiatry. 2004;9(7):711-717.
68. Mill J, Caspi A, Williams BS, et al. Prediction of heterogeneity in intelligence and adult prognosis by genetic polymorphisms in the dopamine system among children with attention-deficit/hyperactivity disorder: evidence from 2 birth cohorts. Arch Gen Psychiatry. 2006;63(4):462-469.
69. Roman T, Schmitz M, Polanczyk GV, Eizirik M, Rohde LA, Hutz MH. Further evidence for the association between attention-deficit/hyperactivity disorder and the dopamine-beta-hydroxylase gene. Am J Med Genet. 2002;114(2):154-158.
70. Bellgrove MA, Hawi Z, Gill M, Robertson IH. The cognitive genetics of attention deficit hyperactivity disorder (ADHD): sustained attention as a candidate phenotype. Cortex. 2006;42(6):838-845.
71. Kieling C, Genro JP, Hutz MH, Rohde LA. The -1021 C/T DBH polymorphism is associated with neuropsychological performance among children and adolescents with ADHD. Am J Med Genet B Neuropsychiatr Genet. 2008;147B(4):485-490.
72. Rapoport JL, Inoff-Germain G. Responses to methylphenidate in attention-deficit/hyperactivity disorder and normal children: update 2002. J Atten Disord. 2002;6(suppl 1):S57-S60.
73. Mehta MA, Owen AM, Sahakian BJ, Mavaddat N, Pickard JD, Robbins TW. Methylphenidate enhances working memory by modulating discrete frontal and parietal lobe regions in the human brain. J Neurosci. 2000;20(6):RC65.
74. Sesack SR, Hawrylak VA, Matus C, Guido MA, Levey AI. Dopamine axon varicosities in the prelimbic division of the rat prefrontal cortex exhibit sparse immunoreactivity for the dopamine transporter. J Neurosci. 1998;18(7):2697-2708.
75. Arnsten AF, Dudley AG. Methylphenidate improves prefrontal cortical cognitive function through α2 adrenoceptor and dopamine D1 receptor actions: relevance to therapeutic effects in attention deficit hyperactivity disorder. Behav Brain Funct. 2005;1(1):2.
76. Arnsten AFT, Castellanos FX. Neurobiology of attention regulation and its disorders. In: Martin A, Scahill L, Charney DS, Leckman JF, eds. Pediatric Psychopharmacology: Principles and Practice. New York, NY: Oxford University Press, Inc.; 2003:99-109.
77. Biederman J, Faraone SV, Milberger S, et al. Is childhood oppositional defiant disorder a precursor to adolescent conduct disorder? Findings from a four-year follow-up study of children with ADHD. J Am Acad Child Adolesc Psychiatry. 1996;35(9):1193-1204.
78. Dyme IZ, Sahakian BJ, Golinko BE, Rabe EF. Perseveration induced by methylphenidate in children: preliminary findings. Prog Neuropsychopharmacol Biol Psychiatry. 1982;6(3):269-273.
79. Aron AR, Dowson JH, Sahakian BJ, Robbins TW. Methylphenidate improves response inhibition in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2003;54(12):1465-1468.
80. Turner DC, Blackwell AD, Dowson JH, McLean A, Sahakian BJ. Neurocognitive effects of methylphenidate in adult attention-deficit/hyperactivity disorder. Psychopharmacology (Berl). 2005;178(2-3):286-295.
81. Bush G, Spencer TJ, Holmes J, et al. Functional magnetic resonance imaging of methylphenidate and placebo in attention-deficit/hyperactivity disorder during the multi-source interference task. Arch Gen Psychiatry. 2008;65(1):102-114.
82. Mehta MA, Sahakian BJ, Robbins TW. Comparative psychopharmacology of methylphenidate and related drugs in human volunteers, patients with ADHD, and experimental animals. In: Solanto MV, Arnsten AFT, Castellanos FX, eds. Stimulant Drugs and ADHD: Basic and Clinical Neuroscience. New York, NY: Oxford University Press; 2001:303-331.
83. Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2002;27(5):699-711.
84. Chamberlain SR, Del Campo N, Dowson J, et al. Atomoxetine improved response inhibition in adults with attention deficit/hyperactivity disorder. Biol Psychiatry. 2007;62(9):977-984.
85. Biederman J, Baldessarini RJ, Wright V, Knee D, Harmatz JS. A double-blind placebo controlled study of desipramine in the treatment of ADD: I. Efficacy. J Am Acad Child Adolesc Psychiatry. 1989;28(5):777-784.
86. Steere JC, Arnsten AF. The alpha-2A noradrenergic receptor agonist guanfacine improves visual object discrimination reversal performance in aged rhesus monkeys. Behav Neurosci. 1997;111(5):883-891.
87. Mao ZM, Arnsten AF, Li BM. Local infusion of an á-1 adrenergic agonist into the prefrontal cortex impairs spatial working memory performance in monkeys. Biol Psychiatry. 1999;46(9):1259-1265.
88. Engberg G, Eriksson E. Effects of á2-adrenoceptor agonists on locus coeruleus firing rate and brain noradrenaline turnover in N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ)-treated rats. Naunyn Schmiedebergs Arch Pharmacol. 1991;343(5):472-477.
89. Biederman J, Melmed RD, Patel A, et al, for the SPD503 Study Group. A randomized, double-blind, placebocontrolled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics. 2008;121(1):e73-e84.
90. Scahill L, Chappell PB, Kim YS, et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry. 2001;158(7):1067-1074.
91. Taylor FB, Russo J. Comparing guanfacine and dextroamphetamine for the treatment of adult attentiondeficit/ hyperactivity disorder. J Clin Psychopharmacol. 2001;21(2):223-228.
92. Franowicz JS, Arnsten AF. The alpha-2a noradrenergic agonist, guanfacine, improves delayed response performance in young adult rhesus monkeys. Psychopharmacology (Berl). 1998;136(1):8-14.
93. Jakala P, Riekkinen M, Sirvio J, et al. Guanfacine, but not clonidine, improves planning and working memory performance in humans. Neuropsychopharmacology. 1999;20(5):460-470.
94. Spencer T, Greenbaum M, Ginsberg LD, Murphy WR, Farrand K. Open-Label Coadministration of Guanfacine Extended Release and Stimulants in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder. Poster presented at: The 161st Annual Meeting of the American Psychiatric Association; May 3-8, 2008; Washington, DC.
95. Sallee FR, McGough JJ, Wigal T, Sea D, Lyne A, Biederman J. Long-term safety and efficacy of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Poster presented at: The 63rd Annual Meeting of the Society of Biological Psychiatry; May 1-3, 2008; Washington, DC.
96. Hunt RD, Minderaa RB, Cohen DJ. Clonidine benefits children with attention deficit disorder and hyperactivity: report of a double-blind placebo-crossover therapeutic trial. J. Am Acad Child Psychiatry. 1985;24(5):617-629.
97. The Tourette's Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology. 2002;58(4):527-536.
98. Sorkin EM, Heel RC. Guanfacine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension. Drugs. 1986;31(4):301-336.
99. Arnsten AF, Cai J, Goldman-Rakic PS. The alpha-2 adrenergic agonist guanfacine improves memory in aged monkeys without sedative or hypotensive side effects. J Neurosci. 1988;8(11):4287-4298.
100. Uhlen S, Porter AC, Neubig RR. The novel alpha-2 adrenergic radioligand [3H]-MK912 is alpha-2C selective among human alpha-2A, alpha-2B and alpha-2C adrenoceptors. J Pharmacol Exp Ther. 1994;271(3):1558-1565.
101. van Zwieten PA, Chalmers JP. Different types of centrally acting antihypertensives and their targets in the central nervous system. Cardiovasc Drugs Ther. 1994;8(6):787-799.
102. Scahill L, Barloon L, Farkas L. Alpha-2 agonists in the treatment of attention deficit hyperactivity disorder. J Child Adolesc Psychiatr Nurs. 1999;12(4):168-173.
103. Arnsten AF. Catecholamine regulation of the prefrontal cortex. J Psychopharmacol. 1997;11(2):151-162.